Nick StaabVice President
Nick Staab is a vice president at Gladstone Place Partners where he advises clients on a variety of communications mandates and strategic situations including activism defense, M&A, equity story development, and other capital markets events.
At Gladstone, Nick has advised on several proxy contests including Illumina’s defense against activist Carl Icahn and Diffusion Pharma’s defense against LifeSci Capital. Recently, Nick has worked on Oklo’s proposed business combination with AltC, a special purpose acquisition company, and advised The Vistria Group on corporate positioning strategies. His M&A experience includes supporting communications for Hillenbrand’s €572-million acquisition of LINXIS Group.
Prior to Gladstone, Nick consulted at leading IR agencies such as ICR and KCSA Strategic Communications, as well as several boutique agencies. During his consultancy career, Nick developed investor communications plans for public companies and provided guidance on high-impact activities such as major organizational changes, IPOs and various corporate developments. Prior to consultancy, Nick supported the investor relations program of Endo Pharmaceuticals, a small cap pharmaceutical manufacturer, through a litigation crisis. Before Endo, Nick provided shareholder surveillance services at Nasdaq for its Fortune 500 clients.
Nick holds a Bachelor of Business Administration in Finance from Temple University.